Evidence of intra-hepatic vascular proliferation remodeling early after cure in experimental schistosomiasis mansoni: An immunohistochemical descriptive study

Experimental Parasitology

Volumn 130, Issue 1, 2012, Pages 58-62

  Abdel Fattah, Nashwa S ^a   Ahmed, Naglaa S ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Angiogenesis; Liver fibrosis; Schistosoma

Indexed keywords

ACTIN; CD34 ANTIGEN; PRAZIQUANTEL; SMOOTH MUSCLE ACTIN; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; FEMALE; IMMUNOHISTOCHEMISTRY; LIVER BLOOD VESSEL; LIVER CIRCULATION; LIVER FIBROSIS; LIVER FUNCTION TEST; LIVER GRANULOMA; LIVER REGENERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHISTOSOMIASIS MANSONI; SINGLE DRUG DOSE; TREATMENT DURATION; VASCULARIZATION;

ANIMALS; ANTHELMINTICS; FEMALE; IMMUNOHISTOCHEMISTRY; LIVER; LIVER CIRRHOSIS; MICE; NEOVASCULARIZATION, PHYSIOLOGIC; PRAZIQUANTEL; SCHISTOSOMIASIS MANSONI;

MUS; SCHISTOSOMA; SCHISTOSOMA MANSONI;

EID: 84855920131     PISSN: 00144894     EISSN: 10902449     Source Type: Journal    
DOI: 10.1016/j.exppara.2011.09.014     Document Type: Article

References (43)

1. Akiyoshi F., Sata M., Suzuki H., Uchimura Y., Mitsuyama K., Matsuo K., Tanikawa K. Serum vascular endothelial growth factor levels in various liver diseases. Dig. Dis. Sci. 1998, 43:41-45.
2. Andrade Z.A., Santana T.S. Angiogenesis and schistosomiasis. Mem. Inst. Oswaldo Cruz 2010, 105(4):436-439.
3. Andrade Z.A., Baptista A.P., Santana T.S. Remodeling of hepatic vascular changes after specific chemotherapy of schistosomal periportal fibrosis. Mem. Inst. Oswaldo Cruz. 2006, 101(Suppl. I):267-272.
4. Arthur M.J. Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis. Am. J. Physiol. Gastrointest. Liver Physiol. 2000, 279:G245.
5. Ballermann B.J. Contribution of the endothelium to the glomerular permselectivity barrier in health and disease. Nephron. Physiol. 2007, 106:19-25.
6. Croquet V., Moal F., Veal N., Wang J., Oberti F., Roux J., Vuillemin E., Gallois Y., Douay O.I., Chappoard D., Catès P. Hemodynamics and antifibrotic effects of losartan in rats with liver fibrosis and portal hypertension. J. Hepatol. 2003, 37:713-780.
7. de Meijer V.E., Sverdlov D.Y., Popov Y., Le H.D., Meisel J.A., Nosé V., Schuppan D., Puder M. Broad-spectrum matrix metalloproteinase inhibition curbs inflammation and liver injury but aggravates experimental liver fibrosis in mice. PLoS One 2010, 5(6):e11256.
8. El-Hoseiny L. Experimental evaluation of propolis-a natural bee product in Schistosoma mansoni infection. Egy. J. Med. Sci. 1999, 20(1):219-232.
9. Fallowfield J.A., Kendall T.J., Iredale J.P. Reversal of fibrosis: no longer a pipe dream?. Clin. Liver Dis. 2006, 10:481-497.
10. Fernandez M., Mejias M., Garcia-Pras E. Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats. Hepatology 2007, 46:1208-1217.
11. Folkman J. Angiogenesis and angiogenesis inhibition: an overview. EXS 1997, 79:1-8.
12. Friedman S.L. Hepatic stellate cells: protean, multifunctional and enigmatic cells of the liver. Physiol. Rev. 2008, 88:125-172.
13. Friedman S.L. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008, 134:1655-1669.
14. Genesca J., Gonzalez A., Mujal A., Cereto F., Segur A.R. Vascular endothelial growth factor levels in liver cirrhosis. Dig. Dis. Sci. 1999, 44:1261-1262.
15. Ghiassi-Nejad Z., Friedman S.L. Advances in anti-fibrotic therapy. Expert. Rev. Gastroenterol. Hepatol. 2008, 2(6):803-816.
16. Giatromanolaki A., Kotsiou S., Koukourakis M.I., Sivridis E. Angiogenic factor expression in hepatic cirrhosis. Mediators Inflamm. 2007, 67:187.
17. Gines P., Cardenas A., Arroyo V., Rodes J. Management of cirrhosis and ascites. N. Engl. J. Med. 2004, 350:1646-1654.
18. Jiao J., Friedman S.L., Aloman C. Hepatic fibrosis. Curr. Opin. Gastroenterol. 2009, 25(3):223-229.
19. Kang D.H., Hughes J., Mazzali M., Schreiner G.F., Johnson R.J. Impaired angiogenesis in the remnant kidney model: II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function. J. Am. Soc. Nephrol. 2001, 12:1448-1457.
20. Kang D.H., Joly A.H., Oh S.W., Hugo C., Kerjaschki D., Gordon K.L., Mazzali M. Impaired angiogenesis in the remnant kidney model: I. Potential role of vascular endothelial growth factor and thrombospondin-1. J. Am. Soc. Nephrol. 2001, 12:1434-1447.
21. Kanse S.M., Liang O., Schubert U., Haas H., Preissner K.T., Doenhoff M.J., Dennis R.D. Characterisation and partial purification of Schistosoma mansoni egg-derived pro-angiogenic factor. Mol. Biochem. Parasitol. 2005, 144(1):76-85.
22. Kitade M., Yoshiji H., Kojima H., Ikenaka Y., Noguchi R., Kaji K., Yoshii J. Leptin-mediated neovascularization is a prerequisite for progression of nonalcoholic steatohepatitis in rats. Hepatology 2006, 44:983-991.
23. Lai W.K., Adams D.H. Angiogenesis and chronic inflammation; the potential for novel therapeutic approaches in chronic liver disease. J. Hepatol. 2005, 42:7-11.
24. Lima C.B., Iglesias K.B., Andrade Z.A. Thalidomide failed to inhibit angiogenesis and fibrosis in hepatic schistosomiasis of the mouse. Mem. Inst. Oswaldo Cruz 2007, 102:883-885.
25. Loeffler D.A., Lundy S.K., Singh K.P., Gerard H.C., Hudson A.P., Boros D.L. Soluble egg antigens from Schistosoma mansoni induce angiogenesis-related processes by up-regulating vascular endothelial growth factor in human endothelial cells. J. Infect. Dis. 2002, 185:1650-1656.
26. Makhlouf M.M., Awad A., Zakhari M.M., Fouad M., Saleh W.A. Vascular endothelial growth factor level in chronic liver diseases. J. Egypt. Soc. Parasitol. 2002, 32:907-921.
27. Medina J., Sanz-Cameno P., García-Buey L., Martín-Vílchez S., López-Cabrera M., Moreno-Otero R. Evidence of angiogenesis in primary biliary cirrhosis: an immunohistochemical descriptive study. J. Hepatol. 2005, 42:124-131.
28. Nagy J.A., Feng D., Vasile E., Wong W.H., Shih S.C., Dvorak A.M., Dvorak H.F. Permeability properties of tumor surrogate blood vessels induced by VEGF-A. Lab. Invest. 2006, 86:767-780.
29. Paternostro C., David E., Novo E., Parola M. Hypoxia, angiogenesis and liver fibrogenesis in the progression of chronic liver diseases. World J. Gastroenterol. 2010, 16(3):281-288.
30. Patsenker E., Popov Y., Stickel F., Schneider V., Ledermann M., Sägesser H., Niedobitek G., Goodman S.L., Schuppan D. Pharmacological inhibition of Integrin AlphaV Beta3 Aggravates experimental liver fibrosis and suppresses hepatic angiogenesis. Hepatology 2009, 50(5):1501-1511.
31. Rocky D.C. Current and future anti-fibrotic therapies for chronic liver disease. Clin. Liver Dis. 2008, 12(4):939.
32. Shi B.M., Wang X.Y., Mu Q.L., Wu T.H., Liu H.J., Yang Z. Angiogenesis effect on rat liver after administration of expression vector encoding vascular endothelial growth factor D. World J. Gastroenterol. 2003, 9:312-315.
33. Souza M.M., Tolentino M., Assis B.C., de Oliveira Gonzalez A.C., Silva T.M.C., Andrade Z.A. Pathogenesis of septal fibrosis of the liver (an experimental study with a new model). Pathol. Res. Pract. 2006, 202:883-889.
34. Souza M.M., Tolentino M., Assis B.C., de Oliveira Gonzalez A.C., Silva T.M.C., Andrade Z.A. Significance and fate of septal fibrosis of the liver. Hepatol. Res. 2006, 35:31-36.
35. Taura K., De Minicis S., Seki E., Hatano E., Iwaisako K., Osterreicher C.H., Kodama Y. Hepatic stellate cells secrete angiopoietin 1 that induces angiogenesis in liver fibrosis. Gastroenterology 2008, 135:1729-1738.
36. Tugues S., Fernandez-Varo G., Munoz-Luque J., Ros J., Arroyo V., Rodes J., Friedman S.L. Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology 2007, 46:1919-1926.
37. Vennervald B.J., Dunne D.W. Morbidity in schistosomiasis: an update. Curr. Opin. Infect. Dis. 2004, 17:439-447.
38. WHO Public health impact of schistosomiasis: disease and mortality. WHO expert. Committee on the control of schistosomiasis. Bull. World Health Organ. 1993, 71:657-662.
39. Wynn T. Cellular and molecular mechanisms of fibrosis. J. Pathol. 2008, 214:199-210.
40. Xu H., Shi B.M., Lu X.F., Liang F., Jin X., Wu T.H., Xu J. Vascular endothelial growth factor attenuates hepatic sinusoidal capillarization in thioacetamide-induced cirrhotic rats. World J. Gastroenterol. 2008, 14(15):2349-2357.
41. Yokomori H., Oda M., Yoshimura K., Nagai T., Ogi M., Nomura M., Ishii H. Vascular endothelial growth factor increases fenestral permeability in hepatic sinusoidal endothelial cells. Liver Int. 2003, 23:467-475.
42. Yoshiji H., Kuriyama S., Fukui H. Angiotensin-I-converting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor. Tumour Biol. 2002, 23:348-356.
43. Yoshiji H., Kuriyama S., Yoshii J., Ikenaka Y., Noguchi R., Hicklin D.J., Wu Y. Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis. Gut 2003, 52:1347-1354.